Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes - PubMed (original) (raw)
Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes
C R Chitambar et al. Am J Hematol. 1991 Jun.
Abstract
The treatment of myelodysplastic syndromes (MDS) is both difficult and controversial. In the current study, we evaluated the efficacy of low-dose 5-azacytidine in the treatment of this disorder. Fifteen patients with MDS were entered on study to be treated with 5-azacytidine by continuous intravenous infusion for 14 days. Doses of the drug ranged from 10 mg/m2/day to 35 mg/m2/day, with most patients receiving 16.5 mg/m2/day. In two patients, the drug was stopped early in the course of treatment because of thrombocytopenia. Thirteen patients completed therapy according to protocol. Three of 13 patients demonstrated a partial response to therapy. Of these three patients, one had an increase in platelet and absolute neutrophil counts, while the other two no longer required support with red cell transfusions. The drug was well tolerated and significant myelosuppression did not occur in most patients. Low-dose 5-azacytidine appears to have activity in the treatment of primary MDS and future studies should consider evaluation of this drug in combination with hematopoietic growth factors.
Similar articles
- FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R. Kaminskas E, et al. Oncologist. 2005 Mar;10(3):176-82. doi: 10.1634/theoncologist.10-3-176. Oncologist. 2005. PMID: 15793220 Review. - Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome.
Wijermans PW, Krulder JW, Huijgens PC, Neve P. Wijermans PW, et al. Leukemia. 1997 Mar;11 Suppl 1:S19-23. Leukemia. 1997. PMID: 9130687 Clinical Trial. - Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.
Silverman LR, Holland JF, Weinberg RS, Alter BP, Davis RB, Ellison RR, Demakos EP, Cornell CJ Jr, Carey RW, Schiffer C, et al. Silverman LR, et al. Leukemia. 1993 May;7 Suppl 1:21-9. Leukemia. 1993. PMID: 7683352 Clinical Trial. - Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome.
Diamantopoulos PT, Kontandreopoulou CN, Symeonidis A, Kotsianidis I, Pappa V, Galanopoulos A, Vassilakopoulos T, Dimou M, Solomou E, Kyrtsonis MC, Siakantaris M, Angelopoulou M, Kourakli A, Papageorgiou S, Christopoulou G, Roumelioti M, Panayiotidis P, Viniou NA; Hellenic MDS Study Group. Diamantopoulos PT, et al. Ann Hematol. 2019 Jun;98(6):1383-1392. doi: 10.1007/s00277-019-03650-w. Epub 2019 Mar 15. Ann Hematol. 2019. PMID: 30877373 - 5-Azacytidine/Azacitidine.
Müller A, Florek M. Müller A, et al. Recent Results Cancer Res. 2010;184:159-70. doi: 10.1007/978-3-642-01222-8_11. Recent Results Cancer Res. 2010. PMID: 20072837 Review.
Cited by
- Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Cogle CR, Scott BL, Boyd T, Garcia-Manero G. Cogle CR, et al. Oncologist. 2015 Dec;20(12):1404-12. doi: 10.1634/theoncologist.2015-0165. Epub 2015 Oct 13. Oncologist. 2015. PMID: 26463870 Free PMC article. Review. - Azacitidine in the management of patients with myelodysplastic syndromes.
Khan C, Pathe N, Fazal S, Lister J, Rossetti JM. Khan C, et al. Ther Adv Hematol. 2012 Dec;3(6):355-73. doi: 10.1177/2040620712464882. Ther Adv Hematol. 2012. PMID: 23606938 Free PMC article. - Epigenetic therapies in MDS and AML.
Griffiths EA, Gore SD. Griffiths EA, et al. Adv Exp Med Biol. 2013;754:253-83. doi: 10.1007/978-1-4419-9967-2_13. Adv Exp Med Biol. 2013. PMID: 22956506 Free PMC article. Review. - Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation.
Holz-Schietinger C, Matje DM, Reich NO. Holz-Schietinger C, et al. J Biol Chem. 2012 Sep 7;287(37):30941-51. doi: 10.1074/jbc.M112.366625. Epub 2012 Jun 21. J Biol Chem. 2012. PMID: 22722925 Free PMC article. - Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.
Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, Fulton R, Schmidt H, Kalicki-Veizer J, O'Laughlin M, Kandoth C, Baty J, Westervelt P, DiPersio JF, Mardis ER, Wilson RK, Ley TJ, Graubert TA. Walter MJ, et al. Leukemia. 2011 Jul;25(7):1153-8. doi: 10.1038/leu.2011.44. Epub 2011 Mar 18. Leukemia. 2011. PMID: 21415852 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous